LIGAND PHARMACEUTICALS INC — Form 8-K
Filed July 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Ligand Pharmaceuticals completed its acquisition of XOMA Royalty Corporation on July 14, 2026, paying $39.00 per share in cash for ~$739 million in total equity value, plus CVRs tied to pending litigation proceeds. The deal adds 7 commercial products (including Roche's VABYSMO, Servier's OJEMDA, Zevra's MIPLYFFA), 14 late-stage programs, and 100+ development-stage assets, expanding Ligand's portfolio from ~100 to 200+ royalty assets. The transaction is projected to add $0.50 EPS in 2026 and $1.50 EPS in 2027 on an adjusted basis.
Why this rating
M&A deal worth ~46% of company's $1.6B market cap, doubles core asset base, immediately accretive, materially reshapes business strategy—but execution risks and integration challenges remain unquantified.
See more from July 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.